Current Report Filing (8-k)
April 12 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported):
April 10, 2019
MANHATTAN SCIENTIFICS, INC.
|
(Exact name of registrant as specified in charter)
|
Delaware
|
|
000-28411
|
|
85-0460639
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
The Chrysler Building
405 Lexington Avenue, 26th Floor
New York, New York, 10174
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, including area code:
(212) 541-2405
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 4.01 Change in Registrants Certifying Accountant
AMC Auditing, LLC. ("AMC"), the independent registered public accounting firm of Manhattan Scientifics, Inc. (the "Company"), announced effective February 1, 2019, that AMC was acquired by a new auditing firm, Prager Metis CPA’s LLC (“Prager”), and that all of the employees of AMC were joining Prager.
As a result, effective April 10, 2019, AMC resigned as the Company's independent registered public accounting firm. The Company's Board of Directors engaged Prager to serve as the Company's independent registered public accounting firm effective April 10, 2019.
The reports of AMC on the financial statements of the Company as of and for the fiscal years ended December 31, 2018, contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the report contained a paragraph stating there was substantial doubt about the Company's ability to continue as a going concern..
During the Company's fiscal years ended December 31, 2018 and the subsequent interim period from December 31, 2018 to the date of this report, and in connection with the audit of the Company's financial statements for such periods, there were no disagreements between the Company and AMC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of AMC, would have caused AMC to make reference to the subject matter of such disagreements in connection with its audit reports on the Company's financial statements.
During the Company's fiscal years ended December 31, 2018, and the subsequent interim period from December 31, 2018 to the date of this report, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.
During the Company's fiscal years ended December 31, 2018, and the subsequent interim period from December 31, 2018 to the date of this report, the Company did not consult with Prager regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.
The Company has provided AMC with a copy of the disclosures in this report and has requested that AMC furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not AMC agrees with the statements in this Item 4.01. A copy of this letter is filed as Exhibit 16.1 to this report.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
MANHATTAN SCIENTIFICS, INC.
|
|
|
|
|
|
Date: April 12, 2019
|
By:
|
/s/ Emmanuel Tsoupanarias
|
|
New York, New York
|
Name:
|
Emmanuel Tsoupanarias
|
|
|
Title:
|
Chief Executive Officer
|
|
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Sep 2023 to Sep 2024